Antibody Screening Blood Test in Karachi at Dr. Essa Lab

Antibody Screening at Dr. Essa Lab

The Antibody Screening test, also known as the Indirect Antiglobulin Test (IAT) or indirect Coombs test, is a vital laboratory investigation performed to detect unexpected, circulating antibodies in the patient’s serum or plasma directed against red blood cell (RBC) antigens. Under normal physiological conditions, individuals do not possess antibodies against red blood cell antigens unless they have been exposed to foreign red cells through blood transfusions, pregnancy, or tissue transplantation—a process known as alloimmunization. Dr. Essa Laboratory & Diagnostic Centre, a premier diagnostic institution in Karachi, Pakistan, utilizes advanced immunohaematology systems to perform this critical screening with unmatched precision.

The clinical significance of the Antibody Screening test is profound. It serves as a cornerstone of pre-transfusion compatibility testing (crossmatching) to prevent acute or delayed hemolytic transfusion reactions, which can be life-threatening. Furthermore, it is an indispensable component of routine prenatal care, particularly for Rh-negative pregnant individuals, to identify antibodies capable of crossing the placenta and causing Hemolytic Disease of the Fetus and Newborn (HDFN). By utilizing state-of-the-art column agglutination technology (gel card systems), Dr. Essa Lab ensures highly sensitive and specific detection of clinically significant antibodies, providing clinicians with the reliable data necessary to make informed therapeutic decisions.

This laboratory investigation is highly specialized, requiring a meticulous approach to specimen collection, processing, and interpretation. At Dr. Essa Lab, our pathology department is staffed by experienced hematologists and laboratory technologists who adhere to international standards of quality control. Whether you are preparing for a planned surgical procedure that may require blood transfusion, undergoing routine prenatal screening, or investigating unexplained hemolytic anemia, the Antibody Screening test at Dr. Essa Lab offers the clinical accuracy and peace of mind you deserve.

Clinical Procedure: What to Expect

Patient Preparation

• No fasting is required for the Antibody Screening test; patients may eat and drink normally prior to the blood draw.
• Inform the healthcare provider and laboratory staff about any recent blood transfusions (within the last 3 months) or tissue transplants.
• Provide a detailed history of pregnancies, including any history of Hemolytic Disease of the Newborn or Rh immunoglobulin (RhIG/Anti-D) administration.
• Disclose all current medications, as certain drugs can induce antibody production or interfere with the laboratory testing process.
• Ensure adequate hydration prior to the blood draw to facilitate easier venous access and a more comfortable experience.

During the Procedure

The procedure is a standard venipuncture performed by a highly trained phlebotomist at Dr. Essa Lab. The patient is comfortably seated, and the phlebotomist identifies a suitable vein, typically in the antecubital fossa of the arm. The area is thoroughly cleansed with an antiseptic solution to prevent contamination. A tourniquet is applied briefly to increase venous pressure, and a sterile, single-use needle is inserted into the vein. Blood is drawn into a tube containing an anticoagulant (usually EDTA) or a serum separator tube. Once the sample is collected, the needle is removed, pressure is applied to the puncture site, and a sterile bandage is placed. The entire process takes approximately 5 to 10 minutes. The specimen is immediately labeled with unique patient identifiers and sent to the immunohaematology department for analysis.

When is an Antibody Screening Performed?

Prenatal Care and Pregnancy Monitoring

During pregnancy, maternal-fetal blood incompatibility can lead to severe complications. Obstetricians routinely order an Antibody Screening test during the first trimester for all pregnant women, and repeat it at 28 weeks for Rh-negative mothers. If an Rh-negative mother is carrying an Rh-positive fetus, any fetal-maternal hemorrhage can stimulate the mother’s immune system to produce anti-D antibodies. This test detects these antibodies early, allowing for timely administration of Rh immunoglobulin (RhIG) to prevent maternal sensitization and protect future pregnancies from Hemolytic Disease of the Fetus and Newborn (HDFN).

Pre-Transfusion Compatibility Testing

Prior to any blood transfusion, it is clinically imperative to ensure compatibility between the donor’s red blood cells and the recipient’s serum. The Antibody Screening test is performed as part of the type and screen protocol. If the screen is negative, the risk of a hemolytic reaction is extremely low, allowing for rapid crossmatching. If the screen is positive, further testing (antibody identification) must be conducted to identify the specific antibody and locate antigen-negative donor blood, ensuring patient safety during transfusion therapy.

Evaluation of Hemolytic Transfusion Reactions

If a patient exhibits symptoms of a transfusion reaction—such as fever, chills, back pain, dark urine, or unexplained hypotension during or after a blood transfusion—an immediate investigation is initiated. The Antibody Screening test is performed on both pre-transfusion and post-transfusion patient samples, alongside the donor unit, to determine if the patient has developed new alloantibodies that are destroying the transfused red blood cells, thereby confirming or ruling out an immune-mediated hemolytic transfusion reaction.

Diagnosis of Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia (AIHA) is a condition where the body’s immune system mistakenly produces autoantibodies against its own red blood cells, leading to premature destruction. Physicians request an Antibody Screening test, often in conjunction with a Direct Antiglobulin Test (DAT), to detect these circulating autoantibodies. Identifying whether these are warm-reactive (IgG) or cold-reactive (IgM) autoantibodies is crucial for determining the underlying cause and guiding appropriate immunosuppressive or supportive therapy.

Post-Transfusion Follow-up and Monitoring

Patients who receive frequent blood transfusions, such as those with thalassemia, sickle cell anemia, or myelodysplastic syndromes, are at a significantly higher risk of developing multiple red cell alloantibodies over time. Regular Antibody Screening is performed as a monitoring tool before each transfusion episode. This continuous surveillance helps hematologists track the development of new antibodies, preventing delayed hemolytic reactions and ensuring the selection of the safest possible blood products for chronically transfused individuals.

What Does an Antibody Screening Detect?

The Antibody Screening test at Dr. Essa Lab is designed to detect a wide array of clinically significant and insignificant antibodies. These include:

• Anti-D antibodies (Rh system)
• Anti-C antibodies (Rh system)
• Anti-c antibodies (Rh system)
• Anti-E antibodies (Rh system)
• Anti-e antibodies (Rh system)
• Anti-K (Kell) antibodies
• Anti-k (Cellano) antibodies
• Anti-Fya (Duffy) antibodies
• Anti-Fyb (Duffy) antibodies
• Anti-Jka (Kidd) antibodies
• Anti-Jkb (Kidd) antibodies
• Anti-M antibodies (MNS system)
• Anti-N antibodies (MNS system)
• Anti-S antibodies (MNS system)
• Anti-s antibodies (MNS system)
• Anti-Lea (Lewis) antibodies
• Anti-Leb (Lewis) antibodies
• Anti-P1 antibodies
• Anti-Lua (Lutheran) antibodies
• Anti-Lub (Lutheran) antibodies
• Warm-reactive autoantibodies (typically IgG)
• Cold-reactive autoantibodies (typically IgM)
• Drug-induced red cell antibodies
• High-titer, low-avidity (HTLA) antibodies
• Multiple antibody specificities (complex mixtures)
• Passive anti-D antibodies from recent RhIG administration
• Naturally occurring antibodies without prior red cell exposure

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Laboratory & Diagnostic Centre, we understand that timely diagnostic results are critical for patient care, especially in emergency transfusion scenarios or high-risk pregnancies. A standard Antibody Screening test is typically processed, and the report is made available within 12 to 24 hours of sample collection. However, if the screening yields a positive result, additional complex testing (antibody identification panel) must be performed to pinpoint the exact antibody specificity, which may extend the reporting time. Patients can conveniently access their diagnostic reports online through the secure Dr. Essa Lab web portal or the dedicated mobile application. Physical reports can also be collected from any of our numerous diagnostic centers and collection points across Karachi and other major cities in Pakistan.

Antibody Screening Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Rh Antibodies (Anti-D, C, c, E, e)	Negative	Positive (Alloimmunization detected, risk of HDFN/transfusion reaction)
Kell Antibodies (Anti-K, k)	Negative	Positive (High risk of severe HDFN and transfusion reactions)
Duffy Antibodies (Anti-Fya, Fyb)	Negative	Positive (Risk of delayed hemolytic transfusion reactions)
Kidd Antibodies (Anti-Jka, Jkb)	Negative	Positive (Associated with severe delayed hemolytic reactions)
MNS Antibodies (Anti-M, N, S, s)	Negative	Positive (Variable clinical significance; Anti-S/s can cause HDFN)
Autoantibodies (Warm/Cold)	Negative	Positive (Indicative of autoimmune hemolytic anemia or underlying disease)
Lewis Antibodies (Anti-Lea, Leb)	Negative	Positive (Usually clinically insignificant, active at room temperature)
Antibody Screen Result	Negative (No atypical antibodies)	Positive (Atypical red cell antibodies present; requires identification)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Antibody Screening?

• Established in 1987 by Prof. Dr. Essa M. Abdulla, offering decades of trusted diagnostic excellence.
• Supervised by highly qualified consultant pathologists and hematology specialists.
• Equipped with state-of-the-art automated immunohaematology analyzers and gel card technology.
• Rigorous internal and external quality assurance programs ensuring maximum accuracy.
• Extensive network of collection centers across Karachi and other major cities for easy access.
• Convenient online reporting system and mobile app for quick access to test results.
• Compassionate, patient-centered care with highly trained phlebotomists minimizing patient discomfort.
• Comprehensive diagnostic integration, allowing seamless follow-up testing if antibodies are detected.